Formycon has become the latest company to report Phase III data for a Stelara (ustekinumab) rival, revealing positive preliminary efficacy and safety data from its “VESPUCCI” trial for its FYB202 proposed biosimilar version.
The study “demonstrates the comparable efficacy of FYB202 to the reference product Stelara in patients with moderate to severe psoriasis...